- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01999881
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Studieoversikt
Status
Forhold
- Stadium IIIA Ikke-småcellet lungekreft
- Stadium IIIB Ikke-småcellet lungekreft
- Småcellet lungekreft i omfattende stadium
- Tilbakevendende småcellet lungekreft
- Tilbakevendende ikke-småcellet lungekreft
- Stadium IV Ikke-småcellet lungekreft
- Frisk, ingen tegn på sykdom
- Småcellet lungekreft i begrenset stadium
- Stadium IA Ikke-småcellet lungekreft
- Stadium IB Ikke-småcellet lungekreft
- Stadium IIA Ikke-småcellet lungekreft
- Stadium IIB Ikke-småcellet lungekreft
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Determine the effect of an eight-week exercise intervention on biomarkers of inflammation, oxidative stress, exercise capacity, and quality of life in lung cancer patients.
SECONDARY OBJECTIVES:
I. Determine the effect of an eight-week exercise intervention on markers of stress and quality of life in the support person of lung cancer patients.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM A: Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the University of Wisconsin Hospital and Clinic (UWHC) and 3 days a week at home over 8 weeks.
ARM B: Patients and their support persons undergo the usual care over 8 weeks.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53715
- UW Health Oncology - 1 South Park
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin, Madison
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- LUNG CANCER PATIENTS: A confirmed diagnosis of any stage lung cancer (non-small cell lung cancer [NSCLC] or small cell lung cancer [SCLC])
- LUNG CANCER PATIENTS: Can be receiving any type of treatment (chemotherapy, radiation therapy, both or neither) are eligible
- LUNG CANCER PATIENTS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
- LUNG CANCER PATIENTS: For patients treated with curative intent, and who have not relapsed, they must be within 1 year of their diagnosis of lung cancer (determined by date of diagnostic pathology sample)
- SUPPORT PERSONS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
Exclusion Criteria:
- LUNG CANCER PATIENTS: Symptomatic heart disease including congestive heart failure or arrhythmia
- LUNG CANCER PATIENTS: Documented myocardial infarction in the last three months
- LUNG CANCER PATIENTS: Central nervous system (CNS) metastases that results in impaired ability to participate in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Any psychological or physical disease that would impair or prevent participation in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Cognitive or reading impairments that would preclude them from completing questionnaires
- LUNG CANCER PATIENTS: Current participation in an exercise program
- SUPPORT PERSONS: Symptomatic heart disease including congestive heart failure or arrhythmia
- SUPPORT PERSONS: Documented myocardial infarction in the last three months
- SUPPORT PERSONS: Cognitive or reading impairments that would preclude them from completing questionnaires
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Arm A (aerobic and exercise training)
Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
|
Korrelative studier
Hjelpestudier
Andre navn:
Receive aerobic and exercise intervention
|
Aktiv komparator: Arm II (usual care)
Patients and their support persons undergo the usual care over 8 weeks.
|
Korrelative studier
Hjelpestudier
Andre navn:
Receive usual care
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in biomarkers of inflammation
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Change in oxidative damage as indicated by serum 8-hydroxydeoxyguanosine (8-oh-dG)
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Change in time to walk 400 m
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Change in physical well-being scores on the Functional Assessment of Cancer Therapy-Lung (FACT-L)
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Change in functional well-being scores on the FACT-L
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in stress scores on the SF-36
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Change in quality-of-life scores on the SF-36
Tidsramme: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Toby Campbell, University of Wisconsin, Madison
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UW13034 (Annen identifikator: University of Wisconsin Carbone Cancer Center)
- P30CA014520 (U.S. NIH-stipend/kontrakt)
- A534260 (Annen identifikator: UW Madison)
- SMPH\MEDICINE\HEM-ONC (Annen identifikator: UW Madison)
- 2013-0752 (Annen identifikator: Institutional Review Board)
- NCI-2013-02185 (Registeridentifikator: NCI Trial ID)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Stadium IIIA Ikke-småcellet lungekreft
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtDiffust storcellet lymfom hos barn | Immunoblastisk storcellet lymfom i barndommen | Barndoms Burkitt lymfom | Ubehandlet akutt lymfatisk leukemi hos barn | Stage I Storcellet lymfom i barndommen | Stage I Childhood Small Noncleaved Cell Lymfom | Stage II Storcellet lymfom i barndommen | Stage II Barndom... og andre forholdForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)FullførtUspesifisert solid barndomssvulst, protokollspesifikk | Primær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Kronisk myelomonocytisk leukemi | Juvenil myelomonocytisk leukemi | Burkitt lymfom | Sekundær akutt myeloid... og andre forholdForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)FullførtEkstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom | Tilbakevendende voksen Burkitt lymfom | Tilbakevendende voksent diffust storcellet lymfom | Tilbakevendende voksent diffust blandet celle lymfom | Tilbakevendende voksent diffust småcellet... og andre forholdForente stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)FullførtPrimær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Tilbakevendende akutt myeloid leukemi hos voksne | Ekstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom og andre forholdForente stater, Italia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)FullførtHIV-infeksjon | Uspesifisert solid barndomssvulst, protokollspesifikk | Primær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Kronisk myelomonocytisk leukemi | Juvenil myelomonocytisk leukemi | Ekstranodal marginalsone... og andre forholdForente stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...FullførtKlarcellet nyrecellekarsinom | Kronisk myelomonocytisk leukemi | Tilbakevendende akutt myeloid leukemi hos voksne | Juvenil myelomonocytisk leukemi | Ekstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom | Tilbakevendende voksen Burkitt lymfom og andre forholdForente stater, Tyskland, Italia
Kliniske studier på laboratoriebiomarkøranalyse
-
Fondation LenvalTilbaketrukketCerebral pareseFrankrike
-
Liao Jian AnRekrutteringHode- og nakkekreftTaiwan
-
Progenity, Inc.FullførtDowns syndrom | Aneuploidi | DiGeorge syndrom | Turners syndrom | Klinefelters syndrom | Kromosomsletting | Edwards syndrom | Patau syndromForente stater
-
Tel-Aviv Sourasky Medical CenterUkjentBenmetastaser | Ortopedisk lidelse | Benneoplasma i hoften (diagnose) | Proksimal femoral metafyseal abnormitet
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig intervensjonItalia
-
Oregon Health and Science University4DMedicalPåmelding etter invitasjonLungesykdommer | KOLS | Luftveissykdom | DyspnéForente stater
-
IRCCS Eugenio MedeaRekrutteringCerebral parese | Ervervet hjerneskadeItalia
-
Duke UniversityTilbaketrukketAntikoagulasjons- og trombosepunkttest (AT-POCT)Forente stater
-
Modarres HospitalFullførtKomplikasjoner | Bildeveiledet biopsi | Nyre GlomerulusIran, den islamske republikken
-
University of California, Los AngelesFullførtHjertefeil | OvervektForente stater